By contrast, the inhibition of IL-6/signal transducer and activator of transcription 3 (STAT3) signaling reduced cancer recurrence in preclinical models of breast, head and neck, and hepatocellular carcinoma [78-80]. The gene discussed is STAT3; the disease is cancer.